title: [Immunomodulators of microbial origin enhance cytotoxicity of human mononuclear leukocytes and reduce metastatic progression of Lewis lung carcinoma in mice].
abstract: Effect of immunomodulators for microbial origin on innate immunity and antitumor system was continued to study. Immunomodificator Immunovac VP-4, purified staphylococcal toxoid and glucosaminyl muramyl dipeptide (GMDP) equally enhanced cytotoxicity of mononuclear leukocytes of peripheral blood of healthy donors. Index of cytotoxicity was 2.78, 2.77 and 2.70 respectively. Reduced metastatic progression of Lewis lung carcinoma in mice was observed after Immunovac VP-4 and GMDP administration. Effectiveness was seen when preparations administered according to schedules including their administration before implantation of the tumor. If preparations were administered number of metastases reduced in 4.4-5.6 times and size of metastases reduced in 7-10 times. Interplay between antitumor activity of studied immunomodulators and cytotoxic activity of NK-cells, which are base effectors of antitumor immune response, are discussed.
authors.forename: N K
authors.initials: NK
authors.lastname: Akhmatova
authors.forename: I B
authors.initials: IB
authors.lastname: Semenova
authors.forename: F V
authors.initials: FV
authors.lastname: Donenko
authors.forename: M V
authors.initials: MV
authors.lastname: Kiselevskiĭ
authors.forename: E A
authors.initials: EA
authors.lastname: Kurbatova
authors.forename: N B
authors.initials: NB
authors.lastname: Egorova
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000276:immunology / Q000627:therapeutic use; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use*; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D003601:Cytotoxicity Tests, Immunologic; D004334:Drug Administration Schedule; D006801:Humans; D007155:Immunologic Factors / Q000276:immunology*; D007274:Injections, Intraperitoneal; D020014:K562 Cells; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D008168:Lung / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D051379:Mice; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis / Q000188:drug therapy; D013208:Staphylococcal Toxoid / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use*; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D001428:Bacterial Vaccines; D007155:Immunologic Factors; D013208:Staphylococcal Toxoid; C088865:VP-4 vaccine; D017778:Vaccines, Combined; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C063429:glucosaminylmuramyl-2-alanine-D-isoglutamine